Key facts: Novartis (NVS) shares -5% after del-desiran miss; delpacibart gains FDA priority
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.